share_log

Lucy Scientific's Fiscal Year: Operating Expenses Rise As Accumulated Deficit Hits Over $44M

Benzinga ·  Oct 18, 2023 05:19

Psychedelics company Lucy Scientific Discovery Inc. (NASDAQ:LSDI) reported its full-year results for the period ended June 30, 2023. Numbers show:

  • Total cash held of $1.67 million, vs. $53,379 held in June 30, 2022.

  • Net product sales of $7,048 vs. zero in the prior fiscal year, reportedly owing to sales of Lucy's new microdose mushroom capsules.

  • Working capital expenses of $2.71 million, vs. $5.81 million by June 30, 2022.

  • Operating expenses totaled $5.85 million, a 68.5% YoY increase as compared to $3.47 million in the prior FY.

  • Net cash flows used in operating activities totaled $4.27 million, a 76.4% YoY increase compared to prior FY's $2.42 million.

  • Total net loss of $8.99 million (or $0.71 per share, basic and diluted) vs. the prior year's $5.86 million (or $0.68 per share, basic and diluted.)

  • Accumulated deficit of $44.4 million, around a 25% YoY increase compared to the $35.4 million in 2022's third quarter close.

The company acutely increased its accumulated deficit during the yearly period, despite new M&As closed during the period, as first reported

Green Market Report's Adam Jackson.

Partnerships, Acquisitions & Product Offerings

During the closing fiscal year, Lucy closed numerous deals with different businesses and partners, including:

  • An all-stock acquisition of long-standing cannabis media outlet High Times Holding's IP, brand and licensing business.

  • The acquisition of e-commerce platform and plant-based wellness brand company Blue Sky Wellness.

  • Partnership with specialized firm Pramantha Group toward attaining key government contracts and grants.

  • Development and offer of new Amanita Muscaria mushroom products through online stores and retail channels.

  • Amendment to Canadian Dealer's License enabling the production of cocaine and heroin toward safe supply offering for governments' public health responses to the drug crisis.

See Also: Another Company Approved To Begin Production Of Psychedelics Under Canadian Dealers License

  • Team up with Canadian advocacy organization TheraPsil for the

  • advancement of legal medical psilocybin access and research.

  • Commercial sale of psilocybin to Hadassah BrainLabs, the center for psychedelics research at the Hebrew University in Jerusalem.

See the company's full financial results and discussion breakdown here.

Photo: Benzinga edit with photo by Pexels and Shutterstock.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment